F. Taieb

Saturable absorption of sorafenib in patients with solid tumors: a population model

O. Mir, F. Goldwasser, R. Coriat, 2012, Investigational New Drugs.

Functional and Clinical Evidence of the Influence of Sorafenib Binding to Albumin on Sorafenib Disposition in Adult Cancer Patients

O. Mir, F. Goldwasser, R. Coriat, 2011, Pharmaceutical Research.

Early Sorafenib-Induced Toxicity Is Associated with Drug Exposure and UGTIA9 Genetic Polymorphism in Patients with Solid Tumors: A Preliminary Study

M. Loriot, O. Mir, J. Golmard, 2012, PloS one.

Variability in Free Mycophenolic Acid Exposure in Adult Liver Transplant Recipients During the Early Posttransplantation Period

F. Conti, Y. Calmus, O. Scatton, 2010, Journal of clinical pharmacology.

Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients

M. Loriot, F. Goldwasser, R. Coriat, 2015, Investigational New Drugs.

A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma.

O. Mir, L. Faivre, F. Goldwasser, 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Comparison of a new enzymatic assay with a high‐performance liquid chromatography/ ultraviolet detection method for therapeutic drug monitoring of mycophenolic acid in adult liver transplant recipients

F. Conti, Y. Calmus, M. Tod, 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma.

F. Goldwasser, M. Tod, S. Ropert, 2009, Clinica chimica acta; international journal of clinical chemistry.